Wiener medizinische Wochenschrift. Supplement最新文献

[Venalpina VI: Phlebology training week, 23-30 January 2010, Pontresina, Engadin, Switzerland. Abstracts]. [Venalpina VI:血液学培训周，2010年1月23-30日，Pontresina, Engadin，瑞士。]摘要]。

Wiener medizinische Wochenschrift. Supplement Pub Date : 2010-01-01 DOI: 10.1007/s10354-009-0732-2

引用次数: 0

[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009]. [奥地利绝经后妇女骨质疏松症药物治疗指南- 2009年更新]。

Wiener medizinische Wochenschrift. Supplement Pub Date : 2009-01-01 DOI: 10.1007/s10354-009-0656-x

Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer

{"title":"[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].","authors":"Hans Peter Dimai, Peter Pietschmann, Heinrich Resch, Elisabeth Preisinger, Astrid Fahrleitner-Pammer, Harald Dobnig, Klaus Klaushofer","doi":"10.1007/s10354-009-0656-x","DOIUrl":"https://doi.org/10.1007/s10354-009-0656-x","url":null,"abstract":"<p><p>Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.</p>","PeriodicalId":76823,"journal":{"name":"Wiener medizinische Wochenschrift. Supplement","volume":" 122","pages":"1-34"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10354-009-0656-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28209289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

[Abstracts of the Annual Meeting of the Austrian Society of Hematology and Oncology, 12-14 April 2007, Vienna, Austria]. [2007年4月12-14日，奥地利维也纳，奥地利血液与肿瘤学会年会摘要]。

Wiener medizinische Wochenschrift. Supplement Pub Date : 2007-01-01 DOI: 10.1007/s10354-007-0396-8

引用次数: 0

Abstracts of the Annual Meeting of the Austrian Society of Hematology and Oncology, 27-29 April 2006, Wels, Austria. 奥地利血液与肿瘤学会年会摘要，2006年4月27-29日，奥地利威尔斯。

Wiener medizinische Wochenschrift. Supplement Pub Date : 2006-01-01